• Business Operation

    Currently, the Group has the following products in the market:

     
    Country of origin
    Market
    PRC
    Hong Kong
    Medical application
    Proprietary products
    		   
    Livaracine®
    PRC
    		Heart & other cardiovascular disease
    Yallaferon®
    PRC
    		Vira-infected disease
    Slounase®
    PRC
    		Shortening bleeding time & reducing loss of blood
    Eyprotor®
    PRC
    		Cornea ulcer
    License-in products
    		   
    Carnitene®
    Italy
    		Cardiac disease
    Ferplex®
    Spain
    		Sideropenic Anaemias
    Aloxi®
    France
    		Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy
    Gelclair®
    Italy
    		Mucositis induced by chemo radiotherapy
    Zanidip®
    Italy
    		Hypertension
    Dafnegin®
    Italy
    		 
    		Candiadis
    Veloderm®
    Italy
    		 
    		Burns and wounds healing
    Gaslon N®
    Japan
    		 
    		Gastric Ulcer and Gastritis
    Brio PTCA Balloon
    Catheter
    Italy
    		 
    		PTCA treatment for cardiovascular disease

    Research & development
    Market focused development
    Expansion through licensing
    Building intellectual property portfolio

    Clinical development
    Established network of opinion leaders in multi-discipline areas
    A clinical development team composed of 15 professionals with
    4 trained physicians
    Local and global trials focus on targeted therapies

    Manufacturing
    Wholly-owned subsidiary Zhaoke Pharmaceutical (Hefei) Co., Ltd located in Hefei, China, comprising 4 GMP-compliant workshops for the production of topical gel, lyophilized powder for injection, small volume parenteral solutions and eye gel

    Regulatory
    5 professionals fully devoted to dossier translation and preparation
    More than 25 years of combined experience

    Sales & marketing
    Extensive network covering every province in the PRC with
    600 partnerships covering all of China, including Hong Kong and Macau.
    250 strong people direct sales force covering 26 cities in China.
    Headquarters in Hong Kong.
    Regional offices in Beijing, Shanghai and Guangzhou

  • Trading Information
    Listed: Main Board of HKEX
    Sector: Pharmaceutical
    Stock code: 950
    Listing date: 15 July 2002
    (Transferred from GEM on 14 May 2010)
    Board Lot: 5,000
    Issued capital: 469,730,437 shares (at 24/11/2011)
    Market Cap: HK$1,409 million (at 24/11/2011)
    P/E ratio: 23.44 (at 24/11/2011)

  • Financial Highlights
    HK$'000
    For nine months ended 30 September
    		 Changes
    2011 2010
    Turnover
    270,025
    171,477
    + 57%
    Gross profit
    201,186
    119,655
    + 68%
    Gross profit margin (%)
    74.5%
    69.8%
    + 4.7pt
    Profit from operations
    66,333
    50,523
    + 31%
    EBITDA
    74,314
    56,287
    + 32%
    Profit attributable to shareholders
    56,984
    41,682
    + 37%
    Earnings per share - Basic
    HK 12.17 cents
    HK 9.52 cents
    + 32%

  • Key Indicators
     
    9 months ended 30 Sep 2011

    9 months ended 30 Sep 2010

    Net Profit Margin
    		 21.1%
    24.3%
    Shareholder's Fund (HK$mn)
    		 283
    177
    Liquidity Analysis Ratios (X)
    Current Ratio
    3.5
    3.4
    Quick Ratio
    2.7
    2.7
    Return on Capital Employed Ratios  (%)
    Return on Assets
    16%
    18%
    Return on Equity
    20%
    24%
    Activity
    Stock Turnover Days
    140
    159
    Trade Debtor Turnover Days
    45
    31
    Capital Structure Analysis Ratios (X)
    Debt/Equity
    		0.27
    0.34

  • Competitive Advantages
    Strong R&D capabilities
       
    Outstanding clinical development capabilities
     
    Strong & experienced team with successful track records:
      ~ 10 studies completed
      ~ 5 ongoing studies
      ~ 4 studies under preparation
       
    Regulatory capabilities for international products
     
    Strong & experienced team with more than 15 years regulatory experience in the PRC
    Possess expertise in clinical pharmacology and other relevant areas
    Successful track records with SFDA as to:
      ~ Import Drug Licenses obtained
      ~ Clinical Study Approvals obtained
       
    Distinguished sales and marketing capabilities with established sales and distribution network in the PRC
     
    A team of more than 200 professional promoters, business development people and medical representives.
    3 management offices in major cities Beijing, Shanghai and Guangzhou plus the Hong Kong headquarters
    An established network of more than 600 local distributors
    Covering more than 5000 hospitals and every province in the PRC
    Successful in portfolio management
    More than 100,000 patients treated monthly
    A win-win partnership between Lee's Pharm and local distributors
       

© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement		 Designed by YSD